Publications from the Nanotechnology Characterization Lab
Recent Publications
Immunological properties of silica nanoparticles: a structure-activity relationship study.
Grunberger JW, Dobrovolskaia MA, Ghandehari H.
Nanotoxicology. 2024; 1-23. [PubMed Abstract]
Current state of nanomedicine drug products: An industry perspective.
Clogston JD, Foss W, Harris D, Oberoi H, Pan J, Pu E, Torrico Guzmán EA, Walter K, Brown S, Lim Soo P.
J Pharm Sci. 2024. [PubMed Abstract]
In vitro assessment of nanomedicines' propensity to cause palmar-plantar erythrodysesthesia: A Doxil vs. doxorubicin case study.
Cedrone E, Ishaq A, Grabarnik E, Edmondson E, Skoczen S, Neun BW, Freer M, Shuttleworth S, Sviland L, Dickinson A, Dobrovolskaia MA.
Nanomedicine. 2024; 62: 102780. [PubMed Abstract]
Nano-mupirocin as Tumor-Targeted Antibiotic: Physicochemical, Immunotoxicological and Pharmacokinetic Characterization, and Effect on Gut Microbiome.
Cern A, Skoczen SL, Snapp KS, Hod A, Zilbersheid D, Bavli Y, Alon-Maimon T, Bachrach G, Wei X, Berman B, Yassour M, Cedrone E, Neun BW, Dobrovolskaia MA, Clogston JD, Stern ST, Barenholz Y.
J Control Release. 2024; 373: 713-726. [PubMed Abstract]
Characterization of Nanoparticles Intended for Drug Delivery, Third Edition.
Editors: Clogston JD, Crist RM, Dobrovolskaia MA, Stern ST.
Methods in Molecular Biology. 2024; 2789: Humana Press, New York, NY. [Link]
Immunostimulation of Fibrous Nucleic Acid Nanoparticles Can be Modulated through Aptamer-Based Functional Moieties: Unveiling the Structure-Activity Relationship and Mechanistic Insights.
Rebolledo LP, Ke W, Cedrone E, Wang J, Majithia K, Johnson MB, Dokholyan NV, Dobrovolskaia MA, Afonin KA.
ACS Appl Mater Interfaces. 2024; 16 (7): 8430-8441. [PubMed Abstract]
Special Issue "Nanotechnology to Overcome the World's Most Critical Health Issues: Liposomes and Beyond-A Themed Issue Dedicated to Professor Yechezkel Barenholz".
Dobrovolskaia MA, Afonin KA.
Molecules. 2023; 28 (12): 4788. [PubMed Abstract]
Detection of Nanoparticles' Ability to Stimulate Toll-Like Receptors Using HEK-Blue Reporter Cell Lines.
Cedrone E, Dobrovolskaia MA.
Methods Mol Biol. 2023; 2709: 241-251. [PubMed Abstract]
Multicolor flow cytometry-based immunophenotyping for preclinical characterization of nanotechnology-based formulations: an insight into structure activity relationship and nanoparticle biocompatibility profiles.
Newton HS, Zhang J, Donohue D, Unnithan R, Cedrone E, Xu J, Vermilya A, Malys T, Clogston JD, and Dobrovolskaia MA.
Front Allergy. 2023; 4: 1126012. [PubMed Abstract]
Change in Lipofectamine Carrier as a Tool to Fine-Tune Immunostimulation of Nucleic Acid Nanoparticles.
Newton HS, Radwan Y, Xu J, Clogston JD, Dobrovolskaia MA, and Afonin KA.
Molecules. 2023; 28(11): 4484. [PubMed Abstract]
Evaluation of nonmodified wireframe DNA origami for acute toxicity and biodistribution in mice.
Wamhoff EC, Knappe GA, Burds AA, Du RR, Neun BW, Difilippantonio S, Sanders C, Edmondson EF, Matta JL, Dobrovolskaia MA, Bathe M.
ACS Appl Bio Mater. 2023; 6(5): 1960-1969. [PubMed Abstract]
Plasma stability and plasma metabolite concentration-time profiles of oligo(lactic acid)(8)-paclitaxel prodrug loaded polymeric micelles.
Repp L, Skoczen SL, Rasoulianboroujeni M, Stern ST, Kwon GS.
AAPS J. 2023; 25(3): 39. [PubMed Abstract]
Target-specific nanoparticle polyplex down-regulates mutant Kras to prevent pancreatic carcinogenesis and halt tumor progression.
Smith JP, Chen W, Shivapurkar N, Gerber M, Tucker RD, Kallakury B, Dasa SSK, Kularatne RN, Stern ST.
Int J Mol Sci. 2023; 24(1): 752. [PubMed Abstract]
Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy.
Mohammad SN, Choi YS, Chung JY, Cedrone E, Neun BW, Dobrovolskaia MA, Yang X, Guo W, Chew YC, Kim J, Baek S, Kim IS, Fruman DA, Kwon YJ.
J Control Release. 2023; 354: 91-108. [PubMed Abstract]
For a more comprehensive list of NCL publications, visit our MyNCBI bibliography page.